MRC1 and breast cancer: In contrast, a recent study by Nalio Ramos et al. demonstrated that in human breast cancer that a FOLR2+CADM1−HLA-DR+ PvTAM subset (which co-express LYVE-1 and MRC1) was associated with CD8+ T-cell infiltration into the TME and identified a role for these cells in priming CD8+ T-cell effector function [13].